Drug Survival of Interleukin (IL) ‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study

ConclusionThe cumulative probability of drug survival of both IL-17 and IL-23 inhibitors was higher than 75% at 24  months, with risankizumab and guselkumab demonstrating to have overall cumulative probabilities ≥ 90%. Biological agent chosen, prior exposure to biologic agents, higher baseline BMI and PASI values, and absence of family history of psoriasis were identified as predictors for drug discontinuati on. Risankizumab, guselkumab, and ixekizumab were less likely to be discontinued than secukinumab.
Source: American Journal of Clinical Dermatology - Category: Dermatology Source Type: research